Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.48 |
| ▸ | FPR2 | P25090 | 6/20 | 0.44 |
| ▸ | FPR3 | P25089 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ESRRB | O95718 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESRRA | P11474 | 1/20 | 0.42 |
| ▸ | ESRRG | P62508 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199600 | 0.81 | RORC (0.51) | RORCFPR2FPR3GPR119 | |
| SCHEMBL16764525 | 0.81 | RORC (0.53) | RORCFPR2FPR3MEN1KMT2A | |
| SCHEMBL1200040 | 0.80 | RORC (0.53) | RORCFPR2FPR3GPR119BACE1 | |
| SCHEMBL4630446 | 0.80 | RORC (0.50) | RORCFPR2FPR3GPR119BACE1 | |
| SCHEMBL22532968 | 0.80 | USP30 (0.49) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL14304640 | 0.80 | TSHR (0.48) | RORCGPR119 | |
| SCHEMBL29691772 | 0.79 | RORC (0.48) | RORCFPR2FPR3MEN1KMT2A | |
| SCHEMBL12988312 | 0.79 | TSHR (0.53) | RORCFPR2FPR3KMT2AESRRB | |
| SCHEMBL1427288 | 0.79 | RORC (0.49) | RORCFPR2FPR3ALDH1A1GPR119 | |
| SCHEMBL24763781 | 0.79 | MAPT (0.43) | MEN1KMT2ALMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | C4 THERAPEUTICS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3953332-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-113677664-A | Tricyclic degradants of IKAROS and AIOLOS | C4医药公司 | 2021-11-19 | — | — | CN | disclosed |
| WO-2020210630-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020210630-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407732-B1 | Tricyclic degraders of Ikaros and Aiolos | CRBN, IKZF1, IKZF3 | RORC 3028/4885FPR2 4827/4885FPR3 4741/4885 |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | CRBN, IKZF1, IKZF3 | RORC 3028/4885FPR2 4827/4885FPR3 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.